SIGA News & Events

SIGA Technologies announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This represents the fourth straight year of a special cash dividend. The amount of the dividend declared is consistent with the level of the dividend declared in March 2024. The dividend is payable on May 15, 2025, to shareholders of record at the close of business on April 29, 2025.

SIGA Technologies announced the appointment of Retired United States Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health. The trial enrollment was stopped in late 2024 when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections in San Francisco. "This study brought us a step forward in better understanding mpox disease and potential treatment strategies," said Jeanne Marrazzo, M.D., M.P.H., director of NIH's National Institute of Allergy and Infectious Diseases, which sponsored and funded the trial. "We are grateful to the study team and participants for their contributions to groundbreaking research on a disease that we still do not know enough about." The Study of Tecovirimat for Mpox began in September 2022 as part of the U.S. whole-of-government response to the clade II mpox outbreak. There are no mpox treatments approved in the United States. STOMP was a randomized international efficacy study that enrolled participants who had been ill with mpox for fewer than 14 days in Argentina, Brazil, Japan, Mexico, Peru, Thailand and the United States, including Puerto Rico. SIGA Technologies provided tecovirimat for the study.

Siga Technologies' antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. Tepoxx is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency, in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses. In partnership with Japan Biotechno Pharma, Siga's exclusive distributor in Japan, Siga has delivered an order of Tepoxx to help build Japan's strategic national stockpile. Tpoxx is approved in the U.S. and Canada for the treatment of smallpox. In the E.U. and U.K., marketed as Tecovirimat-SIGA, it is approved for the treatment of smallpox, mpox, cowpox, and to treat complications following smallpox vaccination.